Taken together with proteomic evidence of alterations in angiogenic and apoptotic pathways, our results suggest value in further in-depth testing of JAM-A as a novel therapeutic target in HER2-positive DCIS patients. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.